<DOC>
	<DOCNO>NCT01001611</DOCNO>
	<brief_summary>The purpose study evaluate confirm hypoglycemic efficacy safety CKD-501 mono therapy patient type 2 diabetes treat daily 24 week comparison placebo .</brief_summary>
	<brief_title>An Evaluation Glycemic Control Effects Mono Therapy CKD-501 Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Diabetes Mellitus classify type 1 diabetes type 2 diabetes mellitus accord cause diabetes onset treatment symptom . In type 2 diabetes , combination insulin resistance insulin deficiency work . Diabetes mellitus cause many complication hospitalization one chronic metabolic disorder diabetes mortality rate gradually increase percentage . CKD-501 highly selective peroxisome proliferator-activated receptor-gamma agonist decrease insulin resistance periphery liver result increased insulin-dependent glucose disposal decrease hepatic glucose output . In vivo , It demonstrate CKD-501 improves even glycemic lipid control comparison rosiglitazone pioglitazone . The aim phase 3 study evaluate efficacy safety CKD-501 daily 24 week monotherapy type 2 diabetes mellitus . Furthermore , extension study additional 28 week design confirm long term safety CKD-501 oral hypoglycemic agent .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Type Ⅱ diabetes mellitus Between 18 year 80 year old The patient take oral hypoglycemic agent since 3 month HbA1c 6.5 9 % screening test drug naive stop take oral hypoglycemic agent 3 month HbA1c 7 10 % screen test BMI 21kg/㎡ 40kg/㎡ Diagnosis type Ⅱ diabetes 3 month Cpeptide level 1.0 ng/ml Condition female contraception method , surgical sterilization menopause Condition male agree use recommendatory appropriate contraception method Agreement write informed consent Type I diabetes , gestational diabetes secondary diabetes Treatment insulin thiazolidinediones within 60 day Fasting Plasma Glucose level 250 mg/dl Triglyceride level 500 mg/dl Uncontrollable hypertension ( Although treat antihypertension agent , systolic blood pressure great 140 mmHg diastolic blood pressure great 90 mmHg ) History myocardial infarction , heart failure , cerebral infarction , hematencephalon unstable angina within 6 month Severe hepatic dysfunction : AST , ALT , Total bilirubin , ALP level equal 2.5 time high upper normal limit ( UNL ) Severe renal dysfunction : Renal failure serum creatinine great 30 % normal limit Anemia reason Needs treatment acute disease , uncontrolled diseae diabetic complication Abnormality thyroid function ( normal TSH range ) History proliferative diabetic retinopathy In treatment concomitant drug severe risk drug interaction investigational drug History cancer within 5 year History drug abuse alcoholism Hepatitis B Antigen ( HBsAg ) test positive Treatment systemic inhalant corticosteroid within 1 month prior Screening Patient experience hypersensitivity reaction , serious adverse event effect treatment glitazones Fertile woman practice contraception appropriate method Pregnant woman nurse mother Has contraindication treatment investigational drug medical psychogenic side An impossible one participate clinical trial legal investigator 's decision Participated trial within 4 week Participating trial present</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>glitazone</keyword>
	<keyword>Type II Diabetes</keyword>
	<keyword>Hypolipidemic</keyword>
	<keyword>oral hypoglycemic agent</keyword>
</DOC>